ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,187.70
0.13%
US Tech 100
17,571.20
-0.24%
다우존스 지수
38,884.26
0.00%
Bitcoin
62,272.51
-0.10%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Ligand Pharmaceuticals Incorporated (LGND)

  7. Ligand Pharmaceuticals Incorporated (LGND) 뉴스

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:LGND
일자시간출처헤드라인심볼기업
2024/03/0803:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0707:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0608:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0206:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0108:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/03/0106:49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2908:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2907:43Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/2721:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1710:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1420:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1405:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/02/1309:42Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/1109:30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0607:40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0506:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2024/01/0506:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0705:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0705:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0122:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/12/0122:20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/2823:01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/1011:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
2023/11/1007:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
 검색 관련기사 보기:NASDAQ:LGND

최근 히스토리

AMEX
XLF
Financial Select Sector
NASDAQ
AMZN
Amazon.com
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
FX
USDGBP
US Dollar vs Sterling
AMEX
XLV
Health Care Select Sector
COIN
SOLUSD
Solana
NASDAQ
MSFT
Microsoft
SPI
SP500
S&P 500
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유